Hepion shares up as FDA clears co's lead candidate for mid-stage trial
21/12/2021 13:54
** Shares of drug developer Hepion Pharmaceuticals Inc
HEPA.O up 5% at $1.27 premarket
** Says U.S. FDA clears its lead candidate CRV431 for
mid-stage study for treatment of hepatocellular carcinoma, a
form of liver cancer urn:newsml:reuters.com:*:nGNX260ZQ5
** Adds a mid-stage study of 300 participants is expected to
start in 2022
** Up to Monday's close, stock down 45% YTD
(Reporting by Leroy Leo)
((Leroy.Dsouza@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement